Work Here?
Maravai LifeSciences
Work Here?
Offers oligonucleotide synthesis and immunohistochemistry
Maravai LifeSciences
Work Here?
Offers oligonucleotide synthesis and immunohistochemistry
Overview
Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.
About Maravai LifeSciences
Industries
Venture Capital
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2014
People at Maravai LifeSciences
People at Maravai LifeSciences who can refer or advise you
Simplify's Take
What believers are saying
- TriLink revenue grew 65% in Q1 2026, driven by strong demand and vaccine orders.
- Expanding enzyme and plasmid DNA capacity strengthens scalable mRNA therapy production globally.
- Refinancing to 2032 preserves capital access for strategic growth initiatives and R&D.
What critics are saying
- 2024 revenue recognition flaws trigger 30–50% risk of reputational damage within 6–12 months.
- Executive investigation by Robbins Geller raises 40–60% chance of SEC enforcement or class actions.
- Overstated goodwill creates 30–45% risk of asset write-downs impairing growth funding.
What makes Maravai LifeSciences unique
- Maravai offers end-to-end mRNA production with GMP suites for nucleic acid therapies.
- Its TriLink division integrates AI-enabled mRNA design with advanced manufacturing capabilities.
- Maravai acquires enzymatic synthesis tech to advance next-gen CRISPR and oligonucleotide manufacturing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2B
Above
Industry Average
Funded Over
3 Rounds
Benefits
Health Insurance
Company Equity
Fertility Treatment Support
Family Planning Benefits
401(k) Retirement Plan
Paid Vacation
Stock Price
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.
SAN DIEGO, March 1, 2025 /PRNewswire/ - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property and assets from Molecular Assemblies, Inc.
Maravai LifeSciences appoints R. Andrew Eckert as Chairman of the Board of Directors.
More recently, Maravai acquired the molecular biology enzyme provider Alphazyme, LLC, in 2022.
Maravai LifeSciences is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Maravai LifeSciences
Industries
Venture Capital
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2014
Maravai LifeSciences is Hiring for 6 Jobs on Simplify!
Find jobs on Simplify and start your career today